New combo therapy aims to tame rare blood vessel disease

NCT ID NCT05329090

Completed Disease control Sponsor: Hopital Foch Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding rituximab to standard steroid treatment helps adults with IgA vasculitis (a disease causing inflamed blood vessels) achieve remission without needing steroids long-term. 75 participants with new or relapsing disease were randomly assigned to receive either rituximab or a placebo, alongside steroids. The goal was to see if more people could stop steroids entirely while staying in remission at 6 and 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab (a drug that depletes certain immune cells) plus glucocorticoids (steroids)
What this could lead to: If it works, this could offer a more effective treatment for IgA vasculitis, reducing the need for long-term steroids and their side effects.
What could go wrong: This is a relatively small phase 3 trial (75 people), and rituximab may not prove better than steroids alone. It also carries risks like infusion reactions and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

immunoglobulin A vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA VASCULITIS

Contacts and locations

Locations

APHM de La Timone

Marseille, 13385, France
CHRU Bretonneau

Tours, 37044, France
CHU Clermont Ferrand

Clermont-Ferrand, 63000, France
CHU Clermont Ferrand

Clermont-Ferrand, 63003, France
CHU Marseille

Marseille, 13005, France
CHU Nantes

Nantes, 44093, France
CHU Nîmes (Caremeau)

Nîmes, 30029, France
CHU Strasbourg

Strasbourg, 67091, France
CHU Toulouse

Toulouse, 31059, France
Hopital La Cavale Blanche

Brest, 29200, France
Hôpital André Grégoire

Montreuil, 93100, France
Hôpital Cochin

Paris, 75679, France
Hôpital Edouard Herriot

Lyon, 69003, France
Hôpital Foch

Suresnes, 92150, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.